Chief Investigator: 

ATR inhibitor and chemoradiotherapy in oesophageal cancer.

This study will test the combination of a novel ATR inhibitor with radiotherapy or chemoradiotherapy in oesophageal cancer. The design is a phase I, open-label, multicentre, 3-stage, schedule-finding trial using TiTE-CRM (Time-to-Event Continual Reassessment Method).

The study is in setup with a planned opening date of August 2018. A CRUK New Agents Committee grant has been awarded for this study (CRUKD/15/011). Site selection will include Oxford, Leeds & Glasgow.

About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate and postdoctoral training programmes for both scientists and clinicians are internationally recognised.